000109602 001__ 109602
000109602 005__ 20230519145418.0
000109602 0247_ $$2doi$$a10.1016/j.euroneuro.2021.01.095
000109602 0248_ $$2sideral$$a123389
000109602 037__ $$aART-2021-123389
000109602 041__ $$aeng
000109602 100__ $$aAmoretti, S.
000109602 245__ $$aIdentifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique
000109602 260__ $$c2021
000109602 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109602 5203_ $$aThe extreme variability in symptom presentation reveals that individuals diagnosed with a first-episode psychosis (FEP) may encompass different sub-populations with potentially different illness courses and, hence, different treatment needs. Previous studies have shown that sociodemographic and family environment factors are associated with more unfavorable symptom trajectories. The aim of this study was to examine the dimensional structure of symptoms and to identify individuals’ trajectories at early stage of illness and potential risk factors associated with poor outcomes at follow-up in non-affective FEP. One hundred and forty-four non-affective FEP patients were assessed at baseline and at 2-year follow-up. A Principal component analysis has been conducted to identify dimensions, then an unsupervised machine learning technique (fuzzy clustering) was performed to identify clinical subgroups of patients. Six symptom factors were extracted (positive, negative, depressive, anxiety, disorganization and somatic/cognitive). Three distinct clinical clusters were determined at baseline: mild; negative and moderate; and positive and severe symptoms, and five at follow-up: minimal; mild; moderate; negative and depressive; and severe symptoms. Receiving a low-dose antipsychotic, having a more severe depressive symptomatology and a positive family history for psychiatric disorders were risk factors for poor recovery, whilst having a high cognitive reserve and better premorbid adjustment may confer a better prognosis. The current study provided a better understanding of the heterogeneous profile of FEP. Early identification of patients who could likely present poor outcomes may be an initial step for the development of targeted interventions to improve illness trajectories and preserve psychosocial functioning.
000109602 536__ $$9info:eu-repo/grantAgreement/ES/FEDER/Una manera de hacer Europa$$9info:eu-repo/grantAgreement/ES/MINECO-ISCIII/CIBERSAM$$9info:eu-repo/grantAgreement/ES/MINECO-ISCIII-FEDER/PI08-0208$$9info:eu-repo/grantAgreement/ES/MINECO-ISCIII-FEDER/PI11-00325$$9info:eu-repo/grantAgreement/ES/MINECO-ISCIII-FEDER/PI14-00612
000109602 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000109602 590__ $$a5.415$$b2021
000109602 592__ $$a1.324$$b2021
000109602 594__ $$a6.9$$b2021
000109602 591__ $$aPHARMACOLOGY & PHARMACY$$b63 / 279 = 0.226$$c2021$$dQ1$$eT1
000109602 593__ $$aBiological Psychiatry$$c2021$$dQ1
000109602 591__ $$aCLINICAL NEUROLOGY$$b48 / 212 = 0.226$$c2021$$dQ1$$eT1
000109602 593__ $$aNeurology$$c2021$$dQ1
000109602 591__ $$aPSYCHIATRY$$b49 / 157 = 0.312$$c2021$$dQ2$$eT1
000109602 593__ $$aPsychiatry and Mental Health$$c2021$$dQ1
000109602 591__ $$aNEUROSCIENCES$$b77 / 275 = 0.28$$c2021$$dQ2$$eT1
000109602 593__ $$aPharmacology (medical)$$c2021$$dQ1
000109602 593__ $$aNeurology (clinical)$$c2021$$dQ1
000109602 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000109602 700__ $$aVerdolini, N.
000109602 700__ $$aMezquida, G.
000109602 700__ $$aRabelo-da-Ponte, F.D.
000109602 700__ $$aCuesta, M.J.
000109602 700__ $$aPina-Camacho, L.
000109602 700__ $$aGomez-Ramiro, M.
000109602 700__ $$0(orcid)0000-0003-2284-7862$$aDe-la-Cámara, C.$$uUniversidad de Zaragoza
000109602 700__ $$aGonzález-Pinto, A.
000109602 700__ $$aDíaz-Caneja, C.M.
000109602 700__ $$aCorripio, I.
000109602 700__ $$aVieta, E.
000109602 700__ $$ade la Serna, E.
000109602 700__ $$aMané, A.
000109602 700__ $$aSolé, B.
000109602 700__ $$aCarvalho, A.F.
000109602 700__ $$aSerra, M.
000109602 700__ $$aBernardo, M.
000109602 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000109602 773__ $$g47 (2021), 112-129$$pEur. neuropsychopharmacol.$$tEUROPEAN NEUROPSYCHOPHARMACOLOGY$$x0924-977X
000109602 8564_ $$s452046$$uhttps://zaguan.unizar.es/record/109602/files/texto_completo.pdf$$yPostprint
000109602 8564_ $$s1992037$$uhttps://zaguan.unizar.es/record/109602/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000109602 909CO $$ooai:zaguan.unizar.es:109602$$particulos$$pdriver
000109602 951__ $$a2023-05-18-14:03:33
000109602 980__ $$aARTICLE